Changes in persistence to basal insulin following the Medicare out-of-pocket cost cap.

Razanne Oueini¹, Ben Shirley², Christie Teigland³, Melissa Castora-Binkley², Scott Bilder³, Kiran Sunkari³, Lynn Pezzullo²

¹Pharmacy Quality Alliance, 5911 Kingstowne Village Pkwy, Ste 130, Alexandria, VA 22314. Email: roueini@pqa.org.

²Pharmacy Quality Alliance, Alexandria, VA.

³Inovalon Inc, Bowie, MD.

PubMed DOI

Abstract

OBJECTIVE: To evaluate changes in persistence to basal insulin following the implementation of the $35 monthly out-of-pocket cost cap for insulin for Medicare beneficiaries. STUDY DESIGN: We completed a retrospective cohort analysis of a nationally representative Medicare Advantage sample from 2022 to 2023. METHODS: We compared precap rates of persistence to basal insulin in 2022 with postcap ra…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.